Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

Retina. 2007 Oct;27(8):1154-6; author reply 1156-8. doi: 10.1097/IAE.0b013e3180ca7daf.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Choroidal Neovascularization / immunology
  • Humans
  • Immunoglobulin Fab Fragments / immunology*
  • Macular Degeneration / complications
  • Macular Degeneration / drug therapy*
  • Macular Degeneration / immunology
  • Randomized Controlled Trials as Topic
  • Ranibizumab
  • Vascular Endothelial Growth Factor A / immunology
  • Visual Acuity

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin Fab Fragments
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Ranibizumab